# Cardea Bio finalizes merger-acquisition of Nanosens Innovations

Cardea Bio (formerly Nanomedical Diagnostics) has finalized its merger-acquisition of Nanosens Innovations, the creators of CRISPR-Chip technology. The deal combines Cardea's graphene biosensor infrastructure with Nanosens' CRISPR-Chip technology to develop DNA-based products.

- Type: Acquisition
- Announced: 2019-10-20
- Where: United States
- Status: completed
- Products: CRISPR-Chip technology, Genome Sensor, graphene biosensors
- Sectors: [Semiconductors and Industrial Electronics](https://endata.com/sectors/semiconductors-electronics.md)

## Companies

- [Cardea Bio](https://endata.com/companies/42804.md) (acquirer)
- [Nanosens Innovations](https://endata.com/companies/42805.md) (target)

## Sources

- [graphene-info.com](https://www.graphene-info.com/cardea-bio-and-nanosens-innovations-merger-acquisition-finalized), 2019-10-20: "Cardea has announced the finalization of their merger-acquisition of Nanosens Innovations, the creators of CRISPR-Chip."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.